This market-beating fund manager is slashing ACRX and SGYP, but upping ATRS.
These stocks were recommended by Smarter Analyst’s newsletter BioPortfolio, a standout investment resource that allows …
These two pharma stocks all have upside of over 100% say top Wall Street analysts.
Take a gander at bullish Q2 plays in biotech from one of the richest men in the business.
The hedge fund guru’s Q2 moves added ECYT gains to his pocket while saving him greater losses in VRX.
Here’s a glimpse into this hedge fund guru’s Q2 moves that reeled back in three biotech players.
James “Jim” Flynn first walked onto the Deerfield Management team seventeen years ago, since a …
A first glance at this hedge fund’s strategic Q2 moves in biotech sector.
Has this billion-dollar fund made the right call on ARRY, VRX, and HIMX?
Three key biopharma trades from the highly-successful $78 billion Renaissance fund